Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections
Starting soon · Phase 4
Conditions studied: Overactive Bladder, Overactive Bladder Syndrome, Urinary Urgency, Urinary Frequency, Urge Incontinence, Neurogenic Bladder
In brief
The purpose of our study is to evaluate the efficacy and safety of different volumes of bladder-numbing medication for pain relief at the time of office bladder Botox injections. This is a randomized prospective, double-blind superiority trial comparing 200 ml 2% lidocaine versus 30 ml 2% lidocaine for office Botox injections.
Key facts
- Study ID
- NCT06695585
- Run by
- University of Louisville
- People needed
- 36
- Starts
- 2024-12-01
- Expected to finish
- 2025-12-01
- Last updated by the study team
- 2024-11-19
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Adult female, >18 years, English-speaking (surveys utilized are not validated in all languages)
- Able to provide informed consent
- Indications: Refractory urge urinary incontinence, Refractory urinary urgency and frequency, Neurogenic bladder (without sensory deficit)
You may not qualify if…
- Untreated urinary tract infection at the time of procedure
- Contra-indication to Botox
- Contraindication to intravesical lidocaine
- Inability to provide informed consent
- Pregnancy, breast-feeding, intending to become pregnant within 6 months of treatment
Where it is running
- University of Louisville Division of Urogynecology and Reconstructive Pelvic Surgery — Louisville, Kentucky, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.